Efficacy and Safety of Polymyxin B in the Treatment of Infections Caused by Multidrug- Resistant Gram-Negative Infections: A Retrospective Review

被引：0

作者：

Oh, H. M. L. ^{[1
]}

Gan, L. H. ^{[1
]}

Wee, I ^{[1
]}

机构：

[1] Changi Gen Hosp, Singapore, Singapore

来源：

NEW APPROACHES IN CORONARY ARTERY DISEASE: PROCEEDINGS OF THE 8TH INTERNATIONAL CONGRESS ON CORONARY ARTERY DISEASE | 2009年

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The objective of the study was to evaluate the safety and efficacy of polymyxin B in the treatment of multidrug-resistant (MDR) gram-negative infections. Over the study period, a total of 39 patients received polymyxin B either as mono or combination therapy. Acinetobacter baurnanii was isolated in 29 patients (76%) and Pseudomonas aeruginosa in 10 patients (26%). Polymyxin B used ranged from 125,000 to 750,000 units per day for a mean duration of 11 days. There were 4 cases of renal toxicity (2 were reversible). There Were 16 deaths (41%). Polymyxin B proved to be a reasonably safe and effective treatment for MDR Acinetobacter and Pseudomonas infections.

引用

页码：151 / 153

页数：3

共 3 条

[1] Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria [J].